BIOMAT Database Logo BIOMAT Database Logo

[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin]. 2010

Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
harunobu.ito@novartis.com

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077597 Vildagliptin A pyrrolidine-carbonitrile derivative and potent inhibitor of DIPEPTIDYL PEPTIDASE 4 that is used in the treatment of TYPE 2 DIABETES MELLITUS. (2S)-(((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile,Galvus,NVP-LAF237,NVP LAF237
D000218 Adamantane A tricyclo bridged hydrocarbon. Diamantane
D054795 Incretins Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially. Glucose-Dependent Insulin-Releasing Hormone,Incretin,Incretin Effect,Incretin Effects,Effect, Incretin,Effects, Incretin,Glucose Dependent Insulin Releasing Hormone,Hormone, Glucose-Dependent Insulin-Releasing,Insulin-Releasing Hormone, Glucose-Dependent

Related Publications

Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
[Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin].
June 2013, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
April 2006, Expert opinion on investigational drugs,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
September 2011, Diabetes, obesity & metabolism,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Dipeptidyl Peptidase-4 inhibitor (Vildagliptin) induced oral mucositis: A case report.
January 2021, Diabetes & metabolic syndrome,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.
April 2014, Expert opinion on drug metabolism & toxicology,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
March 2009, Drug metabolism and disposition: the biological fate of chemicals,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase-4 inhibitor vildagliptin.
January 2019, Journal of diabetes investigation,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
May 2013, Postgraduate medicine,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin.
September 2015, International immunopharmacology,
Harunobu Ito, and Teruaki Wajima, and Masayuki Yamaguchi, and Nobuyuki Mimori, and Kaneo Sekiguchi
Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
March 2009, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!